SC
RXRX icon

Sculptor Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Sculptor Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-349,800
Closed -$1.71M – 415
2025
Q3 		$1.71M Sell
349,800
-100,200
-22% -$526K 0.02% 231
2025
Q2 		$2.28M Buy
+450,000
New +$2.21M 0.03% 216

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sculptor Capital's RXRX Position: Q1 2026 in Review

Sculptor Capital sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 386,000 shares — an estimated $1.58M sold.

Sculptor Capital first reported a position in RXRX in Q1 2024 and held it in 5 quarters. The position peaked at $3.17M in Q1 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Sculptor Capital reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Sculptor Capital sold 386,000 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.58M.
  • Sculptor Capital first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Sculptor Capital's Recursion Pharmaceuticals position peaked at $3.17M in Q1 2024.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Sculptor Capital's 13F filing for Q1 2026, filed 15 May 2026.